Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Gyre Therapeutics (GYRE) following acquisition announcement
-
-
-
-
-
-
-
Gyre Therapeutics (GYRE) Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
-
-
-
-
-
-
-
Gyre Therapeutics (GYRE) Reports In-Line Q4 EPS
-
-
-
-
-
-
414,979 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

